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Abstract
Background: Bael (Aegle marmelos (L.) Corr.) has been widely used in indigenous systems of Indian medicine to
exploit its medicinal properties including astringent, antidiarrheal, antidysenteric, demulcent, antipyretic, antiulcer,
anti-inflammatory and anti cancer activities. The present study aims to evaluate the antioxidative and antiulcer
effect of methanolic extract of unripe fruit of Aegle marmelos (MEAM) against Helicobacter pylori-Lipopolysaccharide
(HP-LPS) induced gastric ulcer in Sprague Dawley (SD) rats.
Methods: Dose and duration of HP-LPS and MEAM were fixed based on ulcer index of gastric tissue of
experimental animals. Various gastric secretory parameters such as volume of gastric juice, free and total acidity,
acid output, pepsin concentration were analyzed. The activities of enzymatic antioxidants (superoxide dismutase,
catalase, glutathione peroxidase, glutathione reductase and glutathione transferase), non-enzymatic antioxidants
(reduced glutathione, vitamin C and vitamin E) and the levels of lipid peroxidation products were measured.
Histological analysis was performed to evaluate the effect of Aegle marmelos on HP-LPS induced gastric ulcer.
Results: Oral administration of HP-LPS (50 μg per animal) for four consecutive days resulted in induction of ulcer
with the increase in gastric secretory parameters such as volume of gastric juice, free and total acidity, acid output,
pepsin concentration. Oral administration of methanolic extract of Aegle marmelos fruit (MEAM) (25, 50, 100, 250
and 500 mg/kg) reduced the gastric ulcer by 2.8 %, 52.4 %, 73 %, 93 % and 93.98 %, respectively, compared to
89.2 % reduction by sucralfate (100 mg/kg). MEAM treatment significantly (p < 0.05) inhibited the increase in gastric
secretory parameters in ulcerated rats, and it also prevented the reduction of enzymatic (superoxide dismutase,
catalase, glutathione peroxidase, glutathione reductase and glutathione transferase) and non-enzymatic antioxidants
(reduced glutathione, vitamin C and vitamin E) after HP-LPS induction. In addition, lipid peroxidation was inhibited
by MEAM in HP-LPS induced rats. Results of histological analysis correlated well with biochemical parameters.
Conclusion: These observations explored the antioxidant properties of MEAM contributing to the gastroprotective
effect in HP-LPS induced gastric ulcer model.
Keywords: Helicobacter pylori lipopolysaccharide, Aegle marmelos, Antioxidants, Gastric ulcer
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Background
Helicobacter pylori (H. pylori) is a highly prevalent bac-
terial gastroduodenal pathogen of humans infecting al-
most 50 % of the world’s population, and most infected
individuals remain asymptomatic [1]. H. pylori is now
recognized as a causative factor of chronic gastritis, gas-
troduodenal ulcer, gastric cancer and mucosa-associated
lymphatic tissue lymphoma [2, 3]. Several factors of H.
pylori mediate cytotoxicity and the inflammatory reac-
tion. Among these are, vacuolating toxin (VacA), ammo-
nium ions produced by urease, cytotoxin associated gene
A (CagA) protein, the type IV secretion system and lipo-
polysaccharide (LPS) [4, 5].
In general, Gram-negative bacterial Lipopolysaccharides
are key inflammation inducers. However, Helicobacter
pylori-Lipolysaccharide (HP-LPS) shows extremely low
endotoxic activity in comparison to typical Gram-negative
bacterial LPS, such as those from Escherichia coli, which
makes it to potentially contribute to the persistence of in-
fection [6–9]. Helicobacter pylori, being a Gram-negative
bacterium that colonizes the gastric mucosa, is recognized
as a primary cause of gastric disease, and its cell-wall
lipopolysaccharide has been identified among the key
virulence factors responsible for eliciting mucosal in-
flammatory responses that characterize gastritis and
duodenal ulcers [10–14]. The gastric mucosal responses
associated with H. pylori infection in humans as well as
those characterizing mucosal inflammatory changes in
the animal model of HP-LPS induced gastritis are mani-
fested by a marked increase in epithelial cell apoptosis
and proinflammatory interleukin expression, excessive
nitric oxide and prostaglandin generation, and the
disturbances in NFκB and MAPK signaling cascades
[15–18]. HP-LPS has been implicated in the stimulation
of pepsinogen and histamine secretion, inhibition of sul-
fated mucin synthesis, and the production of potentially
destructive auto-antibodies, which may all contribute to
the loss of mucosal integrity [19]. In addition, HP-LPS
was shown to bind to the gastric mucosal somatostatin
receptor, thereby interfering with the regulatory effect
of somatostatin on gastric mucosal G cell function [20].
Pathogen-induced inflammation is associated with an
increase in Reactive Oxygen Species (ROS) and Reactive
Nitrogen Species (RNS) production and the activation
of the inflammatory response depletes tissue antioxi-
dants and exposes the host to increased risk of oxidative
stress [21, 22].
Eradication of H. pylori seems to cure both infec-
tion and ulcers. Successful treatment therefore leads
to the resolution of gastritis and reduces the likeli-
hood of ulcer recurrence [23]. The combination of a
proton pump inhibitor (e.g. omeprazole) and antibi-
otics (i.e. ampicillin, amoxicillin, ofloxacin or tetracyc-
line) is curative in up to 90 % of patients [24].
Many infectious diseases are known to be treated
with herbal remedies throughout the history of man-
kind. Plant materials continue to play a major role in
primary health care as therapeutic remedies in many
developing countries. Plants still continue to be
almost the exclusive source of drugs for the majority
of the world's population. The World Health
Organization reported that 80 % of the world's popu-
lation rely chiefly on traditional medicine and a major
part of the traditional therapies involve the use of
plant extracts or their active constituents [25]. Several
plants are used for the treatment of gastric ailments,
including stomach ache and ulcers [26–31]. Medicinal
plants are recognized as rich sources of natural anti-
oxidants that can protect against inflammation-
associated oxidative stress with their added advan-
tages, such as less toxicity, affordability and medicinal
as well as traditional values. One such traditionally
used medicinal plant since ancient times is Aegle
marmelos Correa, commonly known as Bael, which
belongs to the family Rutaceae. Each and every part
of the plant such as fruit, seed, leaf, bark and root is
known for its therapeutic and medicinal value. The
bael fruit pulp contains many functional and bioactive
compounds such as carotenoids, phenolics, alkaloids,
coumarins, flavonoids, terpenoids, and other antioxi-
dants which may protect us against chronic diseases.
A major constituent of the fruit is the mucilage and
marmelosin (0.5 %), a coumarin. In addition, it also
contains many vitamins and minerals including vita-
min C, vitamin A, thiamine, riboflavin, niacin, cal-
cium, and phosphorus [32]. It should be noted that
the unripe fruits are bitter, acrid, sour, and astringent;
aid digestion and stomach irritation; and are useful in
treating diarrhea, dysentery, and stomachalgia [33].
Inspite of its long traditional usage in Indian medi-
cine, antioxidant and antiulcer properties of Aegle
marmelos fruit have not been studied in vivo using
HP-LPS induced Sprague Dawley (SD) rats as a
model. A previous study on gastric ulcer induced by
aspirin in albino rats has shown the protective effect
of Aegle marmelos fruit [34]. In a similar study, the
ripe fruit pulp of AM shows gastrointestinal cytopro-
tective activity in Aspirin-induced, Cold-restraint
stress-induced and Cerebellar lesion-induced ulcer
models through the release of Serotonin (5-hydroxy-
tryptamine; 5-HT) from enterochromaffin (EC) cells
[35]. Hence, the present study was aimed to investi-
gate the antioxidative effect of methanolic extract of
unripe fruit of Aegle marmelos against HP-LPS in-
duced gastric ulcer in SD rats. Secretory parameters
and analyses of antioxidative enzymes were carried
out using biochemical assays. These results were fur-
ther confirmed by histological analysis.
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Methods
Preparation of methanolic extract of unripe fruit of Aegle
marmelos (MEAM)
The fruits of A. marmelos were collected from Maru-
deeswarar temple, Thiruvanmiyur, TamilNadu, India
during the month of March 2009. The plant material
was identified by Dr. Mathivanan, Professor, Centre for
Advanced Study in Botany, University of Madras,
Guindy Campus, Chennai, Tamilnadu, India and the spe-
cimen was deposited in the same.
The fruits were cut open, deseeded, shade dried, and
ground mechanically. Dried fruit material (500 g) was
first defatted with n-hexane (1 L) for 48 h. The residue
was extracted with absolute methanol (1 L) for 48 h.
The extract was filtered, 80 % of the solvent was re-
moved by distillation at atmospheric pressure and the
last trace of methanol was removed under reduced pres-
sure (Yield, 21.86 %).
Animals
Male SD rats weighing 150–200 g were obtained from
the Institute of Basic Medical Science, Chennai, India.
They were acclimatized to animal house conditions, fed
commercial pelleted rat chow (Hindustan Lever Ltd,
Bangalore, India) and had free access to water. All ani-
mals were maintained under standard conditions of
temperature (28 ± 2 °C) and light (12 h light/dark
cycles). The animals were housed in polypropylene cages
(45 × 24 × 15 cm) and fed with standard diet pellets and
water ad libitum. Animals were handled according to
the regulations of the Institutional Animal Ethical Com-
mittee, University of Madras. All the experiments per-
formed on animals were approved and conducted in
accordance with the Institutional Animals Ethics Com-
mittee (IAEC No. 01/084/09).
H. pylori Lipopolysaccharide
HP-LPS is a kind gift from Professor Manfred Kist, Insti-
tut für Medizinische Mikrobiologie und Hygiene, Frei-
burg, Germany. It was prepared by the conventional
method from 26695 strain of H. pylori. The bacteria
grown in Brucella broth with 5 % fetal calf serum was
pelleted by centrifugation, washed twice with 0.9 %
NaCl, heat inactivated for 2 h in steam and washed twice
with 0.9 % NaCl. The pellet was then suspended in 1 mL
0.9 % NaCl and lyophilized. It was stored at 40 C until
further use.
The optimal dose of HP-LPS to induce gastric ulcer-
ation was assessed by oral administration of HP-LPS
suspended in saline at different doses of 10, 25, 50, 75
and 100 μg per day for 4 consecutive days. Gastric ulcer
index was measured as the sum of the length (in mm) of
each lesion according to Okabe et al. [36]. The
concentration of HP-LPS to induce ulcer was deter-
mined based on ulcer index of experimental animals.
Dose determination of MEAM
Male SD rats were divided into 7 groups of six rats. Gas-
tric ulcers were induced in all the groups by 4 days treat-
ment with HP-LPS (50 μg per animal per day). Groups 2
to 6 were treated orally with different doses of MEAM
dissolved in water (25, 50, 100, 250 and 500 mg per kg
body weight) for 10 days after ulcer induction with HP-
LPS. Group 7 rats, which served as reference control,
were treated with Sucralfate (100 mgkg−1 dissolved in
water and administered orally) for 10 days [37].
After the experimental period, the rats of all the
groups were sacrificed by cervical decapitation. The sto-
machs were removed and cut open along the greater
curvature and then examined under a light microscope.
Based on the ulcer index, effective dose of treatment
was determined.
Further work was carried out with the grouping of ani-
mals as below:
Group I: Control
Group II: Induced (HP-LPS alone [50 μg per animal per
day])
Group III: Treated (HP-LPS 50 μg per animal per day +
250 mg of MEAM per kg body weight.
Group IV: Reference control (HP-LPS 50 μg per animal
per day + 100 mg of Sucralfate per kg body weight.
Group V: Drug control (250 mg of MEAM per kg body
weight)
Pyloric ligation
Pyloric ligation was done by the method of Shay
Komarov [38]. After the experimental period, rats were
subjected to pyloric ligation under ether anaesthesia for
the collection of gastric juice. Under light anaesthesia,
the abdomen was opened by a small midline incision
below the xiphoid process; the pyloric portion of the
stomach was slightly lifted out and ligated, avoiding
damage to its blood supply. The stomach was replaced
and the abdominal wall was closed by interrupted
sutures.
Determination of acid secretory parameters
The animals were sacrificed 4 h after pylorus ligation.
Stomach was dissected out, cut open and the gastric
juice was drained into a small beaker, and centrifuged at
2000 rpm for 10 min. The supernatant was collected
and used for the estimation of volume of gastric juice,
pH, free acidity, total acidity, pepsin concentration and
acid output. The volume was noted and expressed as
ml/100 g/4 h and pH was measured using pH meter. Es-
timation of free and total acidity in gastric juice was
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carried out by the method of Card and Marks [39]. Free
acidity and total acidity were determined by titrating
with 0.01 N sodium hydroxide using Toepfer’s reagent
and phenolphthalein as indicator, respectively. The acid-
ity was expressed as mEq/l/100 g and acid output as
mEq/100 g/4 h. Pepsin was assayed according to the
method of Anson [40] using haemoglobin as substrate.
The absorbance of the solution was read at 650 nm. Re-
sults were expressed as μmol of tyrosine liberated/ml.
Preparation of gastric tissue
The stomach was excised, rinsed in ice-cold physio-
logical saline and homogenized in 0.1 M Tris–HCl buf-
fer (pH 7.4), using a tissue homogenizer with a teflon
pestle, at 4 °C. The resultant tissue homogenate was
used for biochemical measurements.
Biochemical analysis
Total protein was estimated by the method of Lowry
et al. [41]. Enzymatic antioxidants were measured in the
gastric tissues. SOD was measured by the method de-
scribed by Misra and Fridovich [42]. CAT and GPx were
measured according to Takahara et al. [43] and Rotruck
et al. [44], respectively. Glutathione reductase (GR) was
analyzed by the method of Staal et al. [45]. Non-
enzymatic antioxidants, namely Vitamin E, C and re-
duced glutathione (GSH) were measured by the method
of Desai [46], Omaye et al. [47] and Ellman [48], respect-
ively. Glutathione-S-transferase activity was assayed by
the method of Habig et al. [49]. LPO was determined in
the gastric tissue by measuring the formation of thiobar-
bituric acid reactive substances (TBARS) according to
the method of Ohkawa et al. [50].
Histological studies
Gastric tissues were initially rinsed with ice-cold 0.9 %
saline to remove the debris adhering to tissues. The tis-
sues were then fixed in 10 % buffered formalin, routinely
processed and embedded in paraffin. Sections (5 mm
thick) were cut and stained with haematoxylin and eosin.
Fig. 1 Dose determination of HP-LPS for the induction of gastric lesions in SD rats. Data are expressed as Mean ± SD for six animals in each group.
Statistical significance: *p < 0.001, all groups vs control
Fig. 2 Effective dose determination of Methanolic extract of Aegle marmelos (MEAM) in HP-LPS induced animals. Data are expressed as Mean ± SD for
six animals in each group. Statistical significance: *p < 0.001; #p <0.05; NS, not significant. a: all groups vs HP-LPS induced; b: all groups vs rats treated
with sucralfate
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The slides were then evaluated under light microscope
(Nikon XDS-1B).
Statistical methods
All the grouped data were evaluated using SPSS/10.0
software. Hypothesis testing method included one-way
analysis of variance (ANOVA) followed by least signifi-
cant difference (LSD) test. p < 0.05 was considered to in-
dicate statistical significance. All the results were
expressed as mean ± S.D. for six rats in each group.
Results
Dose determination of HP-LPS
Figure 1 depicts the dose determination curve of HP-
LPS to induce gastric ulcer in SD rats. Doses of 10 and
25 μg of HP-LPS per day for a period of 4 consecutive
days produced slight increase in ulcer index when
compared with control, whereas it tends to increase
(p < 0.001) drastically with 50, 75 and 100 μg per day
for the same period in a dose dependent manner.
Hence, 50 μg of HP-LPS per day for four days was
considered as the minimum effective dose to induce
gastric ulcer in SD rats.
Dose determination of MEAM
Effective dose determination of MEAM treatment
against HP-LPS-induced gastric ulcers is shown in Fig. 2.
Oral administration of MEAM (25, 50, 100, 250 and
500 mg/kg) reduced the gastric ulcer by 2.8 %, 52.4 %,
73 %, 93 % and 93.98 %, respectively, compared to
89.2 % reduction by sucralfate (100 mg/kg). There was a
significant dose-dependent decrease (p < 0.001) in the
ulcer index of rats treated with MEAM compared with
untreated ulcerated rats. Therefore, 250 mg/kg of
MEAM for 10 days was chosen as the minimum effect-
ive dose of MEAM which offered significant protection.
Hence, this dose was used for further evaluation of the
gastroprotective activity of MEAM.
Effect of MEAM on secretory parameters
MEAM significantly inhibited the increase in
secretory parameters as shown in Table 1. In ulcer-
ated rats (Group II), there was significant increase
(p < 0.05) in volume of gastric juice, free acidity, total
acidity, acid output and pepsin concentration when
compared with that of control. However, these param-
eters were restored to normal levels upon MEAM
treatment (Group III), similar to that of control ani-
mals (Group I). Sucralfate treated animals (IV) also
produced similar results. Drug alone administered an-
imals (Group V) did not show any significant changes
in comparison to that of control animals (Group I).
Effect of MEAM on enzymatic antioxidants and non
enzymatic antioxidants
The differences in the activities of enzymatic antioxi-
dants and in the levels of non-enzymatic antioxidants
are summarized in Tables 2 and 3, respectively. Upon
HP-LPS induction, a significant decrease (p < 0.05) in ac-
tivities of enzymatic antioxidants (SOD, CAT, GPx, GR
Table 1 Effect of MEAM on the levels of acid secretory parameters in gastric juice of experimental rats
Groups Volume of Gastric Juice pH Free acidity Total acidity Acid Output Pepsin concentration
I 1.45 ± 0.10 4.6 ± 0.28 32.69 ± 1.93 58.73 ± 3.95 85.16 ± 5.74 155.13 ± 10.24
II 3.27 ± 0.27a* 1.92 ± 0.14a* 60.17 ± 4.39a* 91.82 ± 5.22a* 300.25 ± 21.03a* 262.91 ± 17.85a*
III 1.65 ± 0.12b* 4.45 ± 0.35b* 33.26 ± 2.28b* 59.97 ± 3.47b* 98.95 ± 7.27b* 174.36 ± 13.03b*
IV 1.7 ± 0.11b* 4.2 ± 0.27b* 33.9 ± 2.26b* 60.66 ± 4.15b* 103.12 ± 7.59b* 180.88 ± 8.87b*
V 1.4 ± 0.10c NS 4.7 ± 0.34c NS 32.41 ± 2.22c NS 58.11 ± 4.65c NS 81.35 ± 5.45c NS 155.18 ± 10.20c NS
Data are expressed as Mean ± S.D. for six animals in each group. Units: volume of gastric juice (ml 100 g−1 4 h−1); free acidity (mEq L−1100 g−1); total acidity (mEq
−1 L 100 g−1); acid output (mEq 100 g−1 4 h−1); pepsin activity (μmol tyrosine liberated mL−1). Statistical significance: *p < 0.05; NS, not significant. a: Group II
compared with Group I. b: Groups III and IV compared with Group II. c: Group V compared with Group I
Table 2 Effect of MEAM on the activities of enzymatic antioxidants in experimental animals
Groups SOD CAT GPx GR GST
I 4.43 ± 0.26 17.63 ± 0.91 206.28 ± 14.49 2.64 ± 0.16 4.82 ± 0.24
II 2.51 ± 0.18a* 9.06 ± 0.61a* 138.28 ± 37.39a* 1.39 ± 0.11a* 3.02 ± 0.19a*
III 4.39 ± 0.30b* 17.32 ± 1.15b* 205.74 ± 15.07b* 2.51 ± 0.15b* 4.8 ± 0.38b*
IV 4.41 ± 0.28b* 17.47 ± 1.24b* 204.93 ± 13.40b* 2.62 ± 0.18b* 4.79 ± 0.26b*
V 4.42 ± 0.20c NS 17.58 ± 1.12c NS 205.62 ± 12.67c NS 2.63 ± 0.22c NS 4.81 ± 0.35c NS
Data are expressed as Mean ± SD for six animals in each group. Units: SOD, Units/mg protein (one unit of the SOD activity is the amount of enzyme required to
give 50 % inhibition of epinephrine auto oxidation); CAT, μmol of H2O2 consumed/min/mg protein; GSH, nmol/g tissue; GPx, nmol GSH oxidized/min/mg protein;
GR, μmol NADPH oxidized/min/mg protein; GST, μmol of 1-chloro-2,4 dinitrobenzene conjugate formed/min/mg protein. Statistical significance: *p < 0.05; NS, not
significant. a: Group II (HP-LPS induced) compared with Group I (Control). b: Groups III (MEAM treated)and IV (Sucralfate treated) compared with Group II (HP-LPS
induced). c: Group V (Drug control) compared with Group I (Control)
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and GST) was observed in Group II animals when com-
pared with that of control animals (Group I). MEAM
treatment to ulcerated rats significantly elevated the ac-
tivities of these enzymes to near normal levels. Highly
significant reduction (p < 0.05) in the levels of non en-
zymatic antioxidants (GSH, vitamin E and vitamin C)
was evident in the HP-LPS induced animals (Group II).
These adverse changes were reversed to normalcy in
Group III (MEAM treated) animals. Group IV and V an-
imals did not show any significant changes when com-
pared to control animals.
Effect of MEAM on lipid peroxidation
Figure 3 depicts the extent of lipid peroxidation in gas-
tric tissue of control and experimental groups of rats. A
remarkable elevation in the levels of TBARS was ob-
served in the HP-LPS induced rats when compared to
control rats. Treatment with MEAM resulted in a
significant decrease (p < 0.05) in these levels when com-
pared to ulcerated animals. However, MEAM alone and
sucralfate treated animals did not show any significant
changes in these levels when compared to that of control
animals.
Histological analysis of gastric mucosa
The effect of MEAM on gastric histology of control and
experimental group of animals is depicted in Fig. 4. The
gastric mucosa of control rats showed normal architec-
ture with perfect intact structures and regular epithelial
lining (Fig. 4a). The gastric mucosa of HP-LPS induced
rats showed ulceration, submucosal oedema, inflamma-
tion and polymorphonuclear infiltration at the ulcer site
(Fig. 4b); whereas, the gastric mucosa of rats treated
with MEAM showed no ulceration, instead exhibited re-
generating epithelium with mild inflammation (Fig. 4c).
However, the gastric mucosa of rats treated with sucral-
fate also showed slight regeneration of superficial epithe-
lium and with less inflammatory cells (Fig. 4d). The
gastric mucosa of drug control animals showed normal
architecture similar to that of control animals (Fig. 4e).
Discussion
Though various pharmacological interventions, alone, or
in combination, have proved to be beneficial in treat-
ment of gastric ulcer in several studies, they are not free
from their adverse side effects. These detrimental effects
have triggered immense interest in a search for alterna-
tive herbal medicines. Hence, this study was aimed to
find the effect of methanolic extract of unripe fruit of
Table 3 Effect of MEAM on the activities of non-enzymatic anti-
oxidants in experimental animals
Groups GSH Vit C Vit E
I 3.92 ± 0.23 7.52 ± 0.33 5.85 ± 0.32
II 1.46 ± 0.10a* 4.64 ± 0.36a* 3.08 ± 0.21a*
III 3.89 ± 0.25b* 7.48 ± 0.55b* 5.8 ± 0.44b*
IV 3.8 ± 0.25b* 7.45 ± 0.46b* 5.75 ± 0.37b*
V 3.88 ± 0.33c NS 7.5 ± 0.54c NS 5.79 ± 0.34c NS
Data are expressed as Mean ± S.D. for six animals in each group. Units: GSH,
μg/mg protein; Vitamin E, μg/mg protein; Vitamin C, μg/mg protein. Statistical
significance: *p < 0.05; NS, not significant. a: Group II (HP-LPS induced)
compared with Group I (Control). b: Groups III (MEAM treated)and IV
(Sucralfate treated) compared with Group II (HP-LPS induced). c: Group V
(Drug control) compared with Group I (Control)
Fig. 3 Effect of MEAM on Lipid Peroxidation in Gastric tissue of Experimental Animals. Data are expressed as Mean ± SD for six animals in each
group. Units: LPO, nmol of MDA released/mg protein. Statistical significance: *p < 0.05; NS, not significant. a: Group II (HP-LPS induced) compared
with Group I (Control). b: Groups III (MEAM treated)and IV (Sucralfate treated) compared with Group II (HP-LPS induced). c: Group V (Drug control)
compared with Group I (Control)
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Aegle marmelos against HP-LPS induced gastric ulcer in
SD rats.
In this study, a reduction in the ulcer index was no-
ticed in MEAM treated group of animals which clearly
points towards the beneficiary effects of the extract.
High gastric acid production in patients significantly de-
velops antrum predominant gastritis and is at increased
risk for duodenal ulcers. Low gastric acid secretion, in
contrast, develops chronic atrophic gastritis and carcin-
oma [51]. H. pylori infection in patients results in signifi-
cant increase in acid output and duodenal ulceration,
indicating a key role of acid in the pathogenesis of gastro
mucosal ulceration. Highly acidic pH (low pH) has been
shown to enhance H.pylori induced NF-κB nuclear bind-
ing [52]. Increased acid secretions by HP-LPS
contributes to mucosal damage of stomach. At glandular
level, HP-LPS can stimulate histamine release from rat
enterochromaffin cells which contributes to increase in
acid secretion [53]. Pathological effects produced by HP-
LPS on gastric mucosa were varied depending on the
strain of the bacterium, which, in turn, depends on the
molecular structure of the LPS preparation. HP-LPS in
its pure form obtained from a known pathological strain
can stimulate acid secretion and pepsinogen [54]. The
present study indicated the stimulated levels of acid se-
cretion by HP-LPS, confirming the role in gastric ulcer-
ation. H. pylori LPS has also been implicated in a variety
of other putative mechanisms of gastric damage that are
less well characterized and require independent verifica-
tion. These include effects on mucus glycosylation, sulfa-
tion and epithelial cell interaction and acid secretion
[53–57].
Gastric acid secretion can be beneficial while it acts as
a part of the host defense mechanism preventing bacter-
ial infection and hence pathogenicity. It has been pro-
posed that the local acid production will determine the
extent of colonization by Helicobacter species in the
stomach, with decreased acid production promoting the
spread of colonization to the acid-producing body of the
stomach as opposed to the increased acid production,
which tends to restrict colonization, predominantly to
the gastric antrum [58]. LPS from H. pylori 26695 also
stimulated acid secretion as it is evident in this study,
confirming its role in gastric mucosal damage. However,
on treatment with MEAM, acid secretion was signifi-
cantly reduced, suggesting its antisecretory role.
Pepsin, a protease present in the gastric lumen, plays a
crucial role in ulceration of the stomach and, in fact,
gastric acid does not cause ulceration in the absence of
pepsin. Pepsinogen, an inactive precursor secreted by
the chief cells of the gastric mucosa, is activated by acid
in the gastric lumen. H. pylori LPS has been implicated
in the stimulation of pepsinogen and histamine secretion
in association with gastric mucosal damage [10] and the
results of the present study coincide with these findings.
The anti-secretory effect of MEAM was manifested by
the attenuation of acid secretory parameters – acidity,
acid output and pepsin activity.
Sucralfate, an ammonium salt of sucrose octasulfate
has been shown to prevent the formation of acute gas-
tric lesions induced by various ulcerogens in experimen-
tal animals [59]. The potency of Sucralfate in healing
and reducing the gastroduodenal ulceration was sup-
ported by several clinical trials [60]. The mechanisms by
which Sucralfate shows the protective and antiulcer ef-
fects were not fully explained but they have been attrib-
uted to the binding of the drug to the defective and
ulcerated mucosa [61, 62], the formation of a protective
barrier over the eroded mucosal surface and decrease of
Fig. 4 Histological analysis of gastric mucosa of control and
experimental animals. Sections stained with Hematoxylin and Eosin were
visualized under light microscope. a Control gastric mucosa shows
normal architecture of epithelial lining b Gastric mucosa of rats induced
with HP-LPS shows marked inflammation, neutrophil infiltration and
mucosal ulceration with sub-mucosal edema c Gastric mucosa of MEAM
treated rats shows no ulcers, mucosal regeneration with mild
inflammatory cells, and mild edema. d Gastric mucosa of rats treated
with Sucralfate also shows similar architecture as that of MEAM e Gastric
mucosa of rats treated with MEAM alone shows normal gastric epithelial
lining similar to that of control. Magnification: 5 X
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pepsin [63, 64]. It is recently reported that Sucralfate
may also stimulate the luminal release of prostaglandins,
which contribute to the protective and ulcer healing
properties of drug [65]. Sucralfate markedly suppresses
H. pylori infection and the accompanying hypersecretion
of acid. These effects are likely to be important mecha-
nisms by which the drug promotes healing of duodenal
ulcers [66]. Hence, sucralfate was used as reference
control.
An important feature of the pathogenesis of H. pyl-
ori infection is its persistence in the inflamed gastric
mucosa progressing towards peptic ulceration and
gastric carcinoma. H. pylori is believed to be a major
aetiological agent that causes chronic gastritis, along
with the other features, including the lymphoid folli-
cles or lymphoid aggregates, surface epithelial degrad-
ation with mucous depletion, and intestinal
metaplasia. One characteristic event in gastritis is an
infiltration of the sub-epithelial gastric lamina propria
by phagocytes, mainly neutrophils and macrophages,
which produce large amounts of ROS (reactive oxy-
gen species) in the host defence reaction [67–69].
There is evidence that H. pylori infection leads to in-
creased production of O2
− via NADPH oxidase in gas-
tric cells, stimulated by lipopolysaccharide as well as
xanthine oxidase, another mechanism for the gener-
ation of oxygen-derived free radicals [70, 71]. The
oxygen radicals, which are produced in gastric epithe-
lial cells infected with H. pylori, may reduce the anti-
oxidant defense mechanism and turn on the
expression of inflammatory genes, adhesion molecules
and mediators stimulating cell proliferation, as well as
defensive molecular chaperones in gastric epithelial
cells [72].
It is evident that an oral administration of H. pylori
LPS can trigger distinct inflammatory responses in rat
gastric mucosa [44]. ROS are believed to be involved in
inflammation, the expression of oncogenes and cell pro-
liferation [68]. These mediators impart oxidative stress
on the gastric epithelium in the immediate vicinity.
Normally, the level of oxidative stress is regulated by
antioxidants, including vitamin C, cellular reduced gluta-
thione etc., but levels of these antioxidants are decreased
during infection. The increased levels of pro-oxidative
factors and decreased levels of antioxidants result in se-
vere oxidative stress that can modulate many processes
in the gastric epithelium [73]. Cells can survive against
chronic oxidative stress by enhancing activities of anti-
oxidant enzymes, thereby protecting cells from DNA
damages. The results of the present study demonstrate
that MEAM strongly increases both the enzymatic and
nonenzymatic antioxidants.
Pharmacological effects of the medicinal plants are
well known for their free-radical scavenging properties.
The bael fruit pulp contains many functional and bio-
active compounds such as carotenoids, phenolics, alka-
loids, coumarins, flavonoids, terpenoids, and other
antioxidants which protect us against chronic diseases.
Total dietary fiber found in this fruit is divided into in-
soluble dietary and soluble dietary fiber (mucilage and
pectin). In addition, it also contains many vitamins and
minerals including vitamin C, vitamin A, thiamine, ribo-
flavin, niacin, calcium, and phosphorus [74–76]. There-
fore, bael fruit is one of the important plants used for
indigenous traditional medicine [77–80], and it is evi-
dent from the above study that Aegle marmelos (Bael)
fruit, containing various active constituents, with their
synergistic activities, proves effective against HP-LPS in-
duced ulcer.
Conclusion
In conclusion, A. marmelos fruit extract shows good
antioxidant activity. Hence, it exerts its antiulcer effect
by inhibiting secretory parameters and activating anti-
oxidant mechanism, thus protecting the gastric mucosa
against HP-LPS induced ulceration.
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